Abstract
The World Health Organization (WHO) estimated 219 million cases of malaria and 435,000 deaths from malaria in 2017. Displaced people suffer additional exposures to malaria and have additional barriers to receiving appropriate care, increasing their risk of suffering and dying from malaria. Some refugees carry subclinical infection and may not present to a health-care provider with signs and symptoms for 3 months or more after they arrive in the United States. While P. falciparum causes most malaria deaths, this chapter further explains the four main species of malaria and their geographic distribution, clinical presentations, and treatments, including recommended prophylactic treatment of refugees. Although malaria is found throughout the tropics, the Centers for Disease Control and Prevention (CDC) recommends that only refugees from highly endemic areas in sub-Saharan Africa should receive prophylactic post-arrival treatment. This chapter outlines presumptive overseas treatment and recommendations for domestic screening.
| Original language | English (US) |
|---|---|
| Title of host publication | Refugee Health Care |
| Subtitle of host publication | An Essential Medical Guide, Second Edition |
| Publisher | Springer International Publishing |
| Pages | 119-126 |
| Number of pages | 8 |
| ISBN (Electronic) | 9783030476687 |
| ISBN (Print) | 9783030476670 |
| DOIs | |
| State | Published - Jan 1 2020 |
Bibliographical note
Publisher Copyright:© Springer Nature Switzerland AG 2020.
Keywords
- Africa
- Antimalarials
- Artemether-lumefantrine
- Artemisinin-based therapy
- Atovaquone-proguanil
- Diagnosis
- Hyperendemic
- Malaria
- Migrant
- Plasmodium falciparum
- Plasmodium malariae
- Plasmodium ovale
- Plasmodium vivax
- Polymerase chain reaction
- Prophylactic treatment
- Rapid antigen test
- Refugees
- Sub-Saharan Africa
- Thick-and-thin smear
- Treatment
